About RNA-binding protein MEX3A
RNA-binding protein MEX3A (MEX3A) is a protein
from Homo sapiens identified by UniProt accession
A1L020, 520 residues long.
MolForge cross-references it against 0 known binders and
95 disease associations.
Target properties
| Protein name | RNA-binding protein MEX3A |
| UniProt accession | A1L020 |
| Gene | MEX3A |
| Organism | Homo sapiens |
| Length | 520 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (95)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.56
- body mass index · score 0.31
- waist circumference · score 0.20
- body height · score 0.20
- lean body mass · score 0.15
- systolic blood pressure · score 0.15
- lysosomal storage disease · score 0.15
- fat body mass · score 0.13
- neoplasm · score 0.10
- urate measurement · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A1L020-F1 | alphafold | PREDICTED | 64.69 | — |
Amino-acid sequence (520 residues)
MPSLVVSGIM ERNGGFGELG CFGGSAKDRG LLEDERALQL ALDQLCLLGL GEPPAPTAGE DGGGGGGGAP AQPAAPPQPA PPPPPAAPPA APTAAPAAQT PQPPTAPKGA SDAKLCALYK EAELRLKGSS NTTECVPVPT SEHVAEIVGR QGCKIKALRA KTNTYIKTPV RGEEPVFMVT GRREDVATAR REIISAAEHF SMIRASRNKS GAAFGVAPAL PGQVTIRVRV PYRVVGLVVG PKGATIKRIQ QQTNTYIITP SRDRDPVFEI TGAPGNVERA REEIETHIAV RTGKILEYNN ENDFLAGSPD AAIDSRYSDA WRVHQPGCKP LSTFRQNSLG CIGECGVDSG FEAPRLGEQG GDFGYGGYLF PGYGVGKQDV YYGVAETSPP LWAGQENATP TSVLFSSASS SSSSSAKARA GPPGAHRSPA TSAGPELAGL PRRPPGEPLQ GFSKLGGGGL RSPGGGRDCM VCFESEVTAA LVPCGHNLFC MECAVRICER TDPECPVCHI TATQAIRIFS
Explore RNA-binding protein MEX3A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets